phrykt

Bone Biologics Corp (BBLG): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of BBLG were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No BBLG insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BBLG short interest

Low short interest. 0.5% of BBLG shares are sold short: about 1 share in 192. Over the last 12 reports the number of shares short went up 509%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 17,632 BBLG shares were sold short, 0.5% of the shares outstanding, down 22.6% from the report before. At the average daily volume of 33,527 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.52%May 15Oct 306.51%

Days to cover

1.0May 15Oct 301.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202617,6320.52%-23%33,5271.0
Oct 15, 202622,7770.83%-54%41,6601.0
Sep 30, 202649,5121.80%+38%517,9701.0
Sep 15, 202635,8531.30%-3%42,7701.0
Aug 31, 202636,9991.34%-76%89,4271.0
Aug 14, 2026156,5905.68%+646%1.56M1.0
Jul 31, 202620,9811.17%-21%27,8471.0
Jul 15, 202626,5601.48%-61%70,9341.0
Jun 30, 202667,2793.75%+1316%201,8081.0
Jun 15, 20264,7530.26%+3%26,2341.0
May 29, 20264,5980.26%+59%21,0871.0
May 15, 20262,8970.16%-72%9,6141.0

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Bone Biologics company events

Bone Biologics filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (listing). The latest was on Sep 29, 2026.

  1. Sep 29, 2026VoteReported shareholder vote results. Filing
  2. Sep 16, 2026ListingBone Biologics Corporation received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets Nasdaq Listing Rule 5550(a)(2)… Filing
  3. Jul 23, 2026AnnouncementShared information with investors. Filing
  4. Jul 16, 2026AnnouncementThe Board of Directors of Bone Biologics Corporation determined to postpone the 2026 annual meeting of stockholders, which was previously scheduled to be held on August 11, 2026. Filing
  5. Jul 9, 2026AgreementBone Biologics Corporation priced a private offering with an investor pursuant to which the Company agreed to sell to the investor pre-funded warrants to purchase 2,112,677 shares of its common stock, par value $0.001 per share, together with Series F warrants to purchase 2,112,677 shares of Common… Filing
  6. Mar 13, 2026AnnouncementBone Biologics Corporation filed a prospectus supplement w ith the U.S. Securities and Exchange Commission in connection with the Company’s “at the market offering” program for the offer and sale of up to $1.06 million shares of the Company’s common stock, par value $0.001 per share, from time to… Filing
  7. Jan 8, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Bone Biologics financials

Famous investors that hold BBLG

1 of the 50 well-known investors we track reported holding BBLG in their latest 13F filing. The largest position is Ken Griffin's, worth $88.9K.

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 202660,028$88.9K0.0%-32%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named BBLG in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Armistice Capital, LLC13G10.0%
Nov 16, 2026Armistice Capital, LLC13G10.0%
Nov 10, 2026Mitchell P. Kopin13G/A10.0%
Nov 10, 2026Mitchell P. Kopin13G/A10.0%

Questions about Bone Biologics Corp (BBLG) stock

Are BBLG insiders buying or selling?

No BBLG insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in BBLG?

As of Oct 30, 2026, 17,632 BBLG shares were sold short, 0.5% of the shares outstanding, down 22.6% from the report before. At the average daily volume of 33,527 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold BBLG?

1 of the 50 well-known investors we track reported BBLG in their latest 13F filing, including Ken Griffin. The largest position is worth $88.9K. See all holders.

Executive pay

Bone Biologics's chief executive was paid a total of $426K for the year ended Dec 31, 2025, up 11% from $385K the year before. In the last 12 months, Bone Biologics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$426KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$431KThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$263KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.